ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $37.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective increased by TD Cowen from $35.00 to $37.00 in a research report sent to investors on Thursday morning,Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the company. Stifel Nicolaus reduced their price target on ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday. Mizuho raised shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $29.00 to $35.00 in a research report on Monday, February 23rd. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, January 5th. Finally, Wolfe Research assumed coverage on shares of ACADIA Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.74.

ACADIA Pharmaceuticals Trading Down 0.3%

Shares of ACADIA Pharmaceuticals stock opened at $24.56 on Thursday. The company has a fifty day moving average price of $25.53 and a 200 day moving average price of $24.44. ACADIA Pharmaceuticals has a twelve month low of $13.40 and a twelve month high of $28.35. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 8.69 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.The company had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $292.54 million. During the same quarter in the previous year, the firm posted $0.86 earnings per share. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Analysts forecast that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares of the company’s stock, valued at $177,898.42. This trade represents a 47.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 26.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 386 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $26,000. Geneos Wealth Management Inc. lifted its holdings in ACADIA Pharmaceuticals by 113.0% during the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 756 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 885 shares in the last quarter. Finally, Transamerica Financial Advisors LLC increased its holdings in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,005 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.